<DOC>
	<DOCNO>NCT02014883</DOCNO>
	<brief_summary>The purpose project study efficacy triheptanoin oil patient GLUT1 deficiency syndrome .</brief_summary>
	<brief_title>Phase II Open Label Study Using Triheptanoin Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS</brief_title>
	<detailed_description>The primary objective study : - evaluate capacity triheptano誰n improve condition patient GLUT1-DS The secondary objective study : - confirm short-term safety triheptano誰n therapy patient GLUT1-DS - evaluate short-term effect triheptano誰n treatment motor function , autonomy , quality life clinical sign patient GLUT1-DS - evaluate effect triheptano誰n brain energy metabolism use non-invasive 31P-MRS spectroscopy activation occipital cortex order measure level high-energy phosphate ( ATP phosphocreatine )</detailed_description>
	<mesh_term>Carbohydrate Metabolism , Inborn Errors</mesh_term>
	<criteria>Mutation SLC2A1 gene Age &gt; 3 year Patient history/frequency seizure movement disorder document least 3 month prior begin study Covered french social security Patients freely agree participate study understand nature , risk benefit study give write informed consent . ( In addition requirement consent parent legal representative , adolescent provide additional informed consent participate clinical trial ) Evidence psychiatric disorder Attendant neurological disorder Comorbid medical condition would render unsuitable study , e.g . HIV , diabetes Pregnant parturient lactate woman Unwillingness inform case abnormal MRI Failure give write informed consent Unable understand protocol Unable participate whole study Absence sign informed consent Persons deprive liberty judicial administrative decision Person subject exclusion period another research Subjects exclusion criterion require french law</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>